Two BRAF inhibitors (BRAFi) targeting the BRAFV600E mutation were approved in Europe and United States for the treatment of patients with advanced melanoma (stages III and IV): vemurafenib and dabrafenib [48,49]. This evidence concerns the gene BRAF and melanoma.